Effect of Long Term Trimetazidine Treatment on Final Myocardial Fibrosis for ST Eleviation Myocardial Infarction

Effect of Long Term Trimetazidine Treatment on Myocardial Final Fibrosis for Acute Myocardial Infarction

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07325955

Acronym

Easy

Enrollment

194

Registered

2026-01-08

Start date

2020-10-01

Completion date

2024-12-01

Last updated

2026-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ST Elevation Myocardial Infarction (STEMI)

Keywords

Acute myocardial infarction, Trimetazidine, Metabolic therapy

Brief summary

Trimetazidine is a agent promoting glucose utilization by limiting fatty-acid oxidation.Trimetazidine could improve cardiac function in patients with ischemic heart disease. We aimed to explore effect of Trimetazidine on final myocardial fibrosis for patients with ST-elevation myocardial infarction (STEMI) in real world clinical practice. In this observational study, we investigated the effect of long-term treatment with trimetazidine on the final extent of myocardial fibrosis measured by cardiac magnetic resonance 6 months after infarction in real world clinical practice.

Detailed description

This study is an prospective observational real-world clinical research. We evaluated the effect of long term trimetazidine treatment after the primary percutaneous coronary intervention (PCI), the myocardial infarction size in STEMI patients could be further reduced by metabolic regulation therapy. This study contributes to the development of standardized treatment procedure for STEMI patients.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

Diagnosed STEMI patients within one day after reperfusion threapy; Have performed the primary PCI procedure; Sign the informed consent form for this cohort study

Exclusion criteria

Mechanical complications; Cardiogenic shock; Malignant tumors, severe infection, hepatic or renal failure, respiratory failure, or other short-term progressive diseases

Design outcomes

Primary

Measure	Time frame	Description
myocardial fibrosis measured by cardiac magnetic resonance imaging	6 months after infarction	Delayed enhancement of cardiac magnetic resonance imaging showed the myocardial fibrosis after infarction

Countries

China

Outcome results